BIODEXA PHARMACEUTICALS-ADR (BDRX) Stock Price, Quote, News and Overview
NASDAQ:BDRX - Nasdaq - US59564R8079 - ADR - Currency: USD
BDRX Quote, Performance and Key Statistics
BIODEXA PHARMACEUTICALS-ADR
NASDAQ:BDRX (2/12/2025, 8:00:01 PM)
After market: 4.78 -0.02 (-0.42%)4.8
-0.14 (-2.83%)
The current stock price of BDRX is 4.8 USD. In the past month the price increased by 14.83%. In the past year, price decreased by -87.61%.
BDRX Latest News and Analysis
Unusual volume stocks in Wednesday's session
Discover the stocks with unexpected trading volume in today's session on the US markets.
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
Biodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer-Causing Condition: Retail Confidence Peaks
The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer.
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a therapeutic...
BDRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.07 | 341.06B | ||
| AMGN | AMGEN INC | 14.89 | 158.60B | ||
| GILD | GILEAD SCIENCES INC | 22.41 | 128.75B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1562.76 | 116.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.55 | 72.95B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.81B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.82B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.80B | ||
| NTRA | NATERA INC | N/A | 22.70B | ||
| BIIB | BIOGEN INC | 8.17 | 19.44B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.28 | 16.55B |
Related stock screener links
About BDRX
Company Profile
Biodexa Pharmaceuticals PLC is a GB-based company operating in Biotechnology industry. The company is headquartered in Abingdon, Oxfordshire and currently employs 21 full-time employees. The company went IPO on 2014-12-08. Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
Company Info
BIODEXA PHARMACEUTICALS-ADR
1 Caspian Point, Caspian Way
Abingdon OXFORDSHIRE GB
Employees: 21
Company Website: https://www.biodexapharma.com/
Phone: 4401235888300
BDRX FAQ
What is the stock price of BDRX?
The current stock price of BDRX is 4.8 USD.
What is the symbol for BIODEXA PHARMACEUTICALS-ADR stock?
The exchange symbol of BIODEXA PHARMACEUTICALS-ADR is BDRX and it is listed on the Nasdaq exchange.
On which exchange is BDRX stock listed?
BDRX stock is listed on the Nasdaq exchange.
Is BDRX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for BDRX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of BDRX.
Does BDRX stock pay dividends?
BDRX does not pay a dividend.
What is the Price/Earnings (PE) ratio of BDRX?
BDRX does not have a PE ratio as the earnings reported over the last twelve months were negative (-73.72).
What is the Short Interest ratio of BDRX stock?
The outstanding short interest for BDRX is 1.09% of its float.
BDRX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BDRX. When comparing the yearly performance of all stocks, BDRX is a bad performer in the overall market: 89.91% of all stocks are doing better.
BDRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BDRX. Both the profitability and financial health of BDRX have multiple concerns.
BDRX Financial Highlights
Over the last trailing twelve months BDRX reported a non-GAAP Earnings per Share(EPS) of -73.72. The EPS increased by 98.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.82% | ||
| ROE | -78.14% | ||
| Debt/Equity | 0.02 |
BDRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to BDRX. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 80.32% and a revenue growth -100% for BDRX